SLC11A2 and diabetes mellitus: Further in vivo study on an in-depth understanding of how DMT1-silencing-induced signaling pathways contribute to the β-cell survival is needed, and DMT1 inhibition might provide more cues for the development of therapeutic strategies in diabetes.